A Phase 1b, Multi-center, Study of METREXASSISTTM (Parenteral TK-112690) Administered in Combination with Methotrexate as a Weekly Infusion to Subjects with SCCHN Undergoing Treatment with Methotrexate. A Dose Escalation/Safety study with No Control
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2018
At a glance
- Drugs TK 112690 (Primary) ; Methotrexate
- Indications Mucositis
- Focus Adverse reactions
- Sponsors Tosk
- 11 Sep 2018 Status changed from recruiting to completed.
- 05 Feb 2018 According to a Tosk media release, positive preliminary results are been announced for the first three patients.
- 21 Aug 2017 Status changed from not yet recruiting to recruiting.